Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUTH study of dasatinib + quercetin for fibrotic NAFLD
NL-OMON60890Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic fibrosis comparing Dasatinib + quercetin with Placebo control (2 arms). Primary endpoint: Primary histologic fibrosis response. Started Oct 2024; status: completed.
02
Drugs
dasatinibquercetin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hepatic fibrosis
Beyond the preview
Go deeper on NL-OMON60890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60890.